Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy
| العنوان: | Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy |
|---|---|
| المؤلفون: | Filip K. Knop, Mikkel B. Christensen, Andreas Brønden, Signe Vinsand Naver |
| المصدر: | Expert Opinion on Drug Metabolism & Toxicology. 11:1493-1503 |
| بيانات النشر: | Informa Healthcare, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Phases of clinical research, Type 2 diabetes, Pharmacology, Toxicology, Placebo, Glucagon-Like Peptide-1 Receptor, chemistry.chemical_compound, Clinical Trials, Phase II as Topic, Pharmacokinetics, Glucagon-Like Peptide 1, Weight Loss, Humans, Hypoglycemic Agents, Medicine, Adverse effect, Clinical Trials, Phase I as Topic, Dose-Response Relationship, Drug, business.industry, General Medicine, medicine.disease, Albiglutide, Clinical Trials, Phase III as Topic, Diabetes Mellitus, Type 2, chemistry, Pharmacodynamics, Glycated hemoglobin, business |
| الوصف: | Introduction: Albiglutide is a once-weekly, glucagon-like peptide-1 receptor agonist approved during 2014 in both the US and Europe for the treatment of adults with type 2 diabetes. The recommended dose is 30 mg with the possibility of uptitration to 50 mg based on individual glycemic response.Areas covered: Here, we outline the pharmacokinetics, pharmacodynamics and clinical efficacy data originating from the Phase I – III studies carried out to obtain market authorization for albiglutide.Expert opinion: The eight Phase III clinical trials have provided evidence that albiglutide in monotherapy and as an add-on to different background therapies confers placebo-corrected reductions in glycemia with changes in glycated hemoglobin of −0.8 to −1.0%. Albiglutide did not cause significant weight loss compared to placebo, but the adverse events profile was favorable with gastrointestinal adverse events occurring only slightly more with albiglutide than placebo. There is no clinical evidence of an effect of albig... |
| تدمد: | 1744-7607 1742-5255 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6335b06de86ef578d5c56fdabcac31eTest https://doi.org/10.1517/17425255.2015.1068288Test |
| رقم الانضمام: | edsair.doi.dedup.....b6335b06de86ef578d5c56fdabcac31e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447607 17425255 |
|---|